Introduction: Low serum testosterone is related to increased mortality in male dialysis patients. An association of vitamin D status with serum androgen levels with concordant seasonal variation has been described, but it is undecided whether vitamin D supplementation improves testosterone levels.
Methods: In a randomized, placebo-controlled, and double-blind manner, we investigated the effects of an oral vitamin D supplementation in healthy subjects and hemodialysis patients on testosterone levels. One hundred three healthy individuals received cholecalciferol 800 IE/day (n = 52) or placebo (n = 51) for 12 weeks. Thirty-three hemodialysis patients received cholecalciferol adapted to their serum levels following current guidelines (n = 15) or placebo (n = 18) for 12 weeks.
Results: In healthy individuals, 25(OH)D3 levels rose significantly in the verum group (38.1 ± 13.7 vs. 72.5 ± 15.4 nmol/L, p < 0.001), whereas in the placebo group, levels dropped (37.7 ± 14.7 vs. 31.9 ± 13.1, p < 0.001). Testosterone levels did not change significantly (verum, males: 20.9 ± 6.6 vs. 20.5 ± 7.9 nmol/L, p = 0.6; verum, females: 0.9 ± 0.5 vs. 0.92 ± 0.5, p = 0.4; placebo, males: 18.5 ± 10.2 vs. 21.8 ± 16.5, p = 0.07, placebo, females: 1.6 ± 4.2 vs. 1.6 ± 4.9, p = 0.6). In dialysis patients, the mean cholecalciferol level was only 32.3 ± 17.8 nmol/L, with only 2% of the values being within the normal range. Cholecalciferol levels normalized in the verum group (29.4 ± 11.2 vs. 87.8 ± 22.3, p < 0.001), whereas levels dropped further in the placebo group (33.6 ± 16.6 vs. 24.6 ± 8.0 nmol/L, p < 0.001). Testosterone levels did not change significantly (verum, males: 8.0 ± 3.7 vs. 7.8 ± 3.8, p = 0.8; verum, females: 1.3 ± 1.0 vs. 1.2 ± 1.0 nmol/L, p = 0.5; placebo, males: 11.9 ± 5.0 vs. 11.6 ± 4.0 nmol/L, p = 0.6; placebo, females: 0.8 ± 0.5 vs. 0.7 ± 0.4 nmol/L, p = 0.8).
Conclusion: Serum testosterone levels in hemodialysis patients and healthy individuals are independent from vitamin D status and cannot be significantly increased by cholecalciferol supplementation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491494 | PMC |
http://dx.doi.org/10.1159/000516636 | DOI Listing |
Int Ophthalmol
January 2025
University of Pittsburgh, UPMC Eye Center, 203 Lothrop Street, Pittsburgh, PA, 15213, USA.
Purpose: To analyze levels of salivary steroids, including 17-OH-progesterone (17-OHP), androstenedione, dehydroepiandrosterone, cortisol, cortisone, progesterone, testosterone, and estradiol, in patients with acute central serous chorioretinopathy (CSCR) patients.
Methods: Acute CSCR patients and healthy individuals were included in this observational case-control study. Levels of salivary steroids were determined by high-performance liquid chromatography with tandem mass spectrometry detection.
Eur J Drug Metab Pharmacokinet
January 2025
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
Background And Objective: A gonadotropin-releasing hormone (GnRH) agonist such as leuprolide is widely used to achieve sustained suppression of testosterone levels, which play a critical role in the treatment of prostate cancer. Recent advances in drug delivery systems have led to the development of long-acting depot formulations, such as the 6-month intramuscular (IM) leuprolide formulation, which aim to simplify dosing and improve convenience for both patients and healthcare providers. Exploring extended dosing intervals for such formulations represents a promising approach to further optimize treatment regimens, potentially balancing efficacy with patient-centered care.
View Article and Find Full Text PDFJ Mol Histol
January 2025
Clinical Pharmacology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Type 2 diabetes mellitus (T2DM) adversely affects various organs, including the brain and its blood barrier. In addition to the brain, hyperglycemia damages the testes. The testes possess blood-tissue barriers that share common characteristics and proteins with the blood-brain barrier (BBB), including breast cancer-resistant protein (BCRP).
View Article and Find Full Text PDFChemosphere
January 2025
College of Pharmacy, Dongduk Women's University, Seoul, 02748, South Korea. Electronic address:
Pyrethroids, which are widely utilized in agriculture, household products, and public health for their potent insecticidal properties, elicit significant concerns regarding their potential endocrine-disrupting effects. However, previous studies have yielded inconsistent data, largely due to the absence of a standardized screening system. To address this limitation, the present study introduces an Integrated Approach to Testing and Assessment (IATA) to evaluate the endocrine-disrupting potential of pyrethroids, aligned with the Adverse Outcome Pathway (AOP) framework.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
January 2025
Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University (Chongqing Health Center for Women and Children), Chongqing, China.
Context: PCOS pregnancies are linked to metabolic disorders affecting maternal and fetal outcomes, with maternal metabolites differing from those in normal pregnancies.
Objective: To investigate the metabolic communication at the maternal-fetal interface in PCOS pregnancies.
Design: Placenta and umbilical cord serum were analyzed using gas chromatography-mass spectrometry.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!